Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Temple

Showing results (1-10 of 394) with videos related to

Pageof 40
Sort By:
JAMA|March 10, 1999
Meta-analysis and epidemiologic studies in drug development and postmarketing surveillanceR Temple
Clinical Pharmacology and Therapeutics|December 1, 1987
The clinical investigation of drugs for use by the elderly: Food and Drug guidelinesR Temple
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 1, 1985
FDA letter to radioactive drug research chairpersonsR Temple
American Heart Journal|March 31, 2000
Current definitions of phases of investigation and the role of the FDA in the conduct of clinical trialsR Temple
The American Journal of Cardiology|May 30, 1998
The challenge of regulating development and approval of drugs with pleiotropic action in cardiovascular diseaseR Temple
Clinical Pharmacology and Therapeutics|July 17, 2007
Quantitative decision analysis: a work in progressR Temple
Clinical Pharmacology and Therapeutics|October 15, 2010
Enrichment of clinical study populationsR Temple
The Medical Clinics of North America|September 1, 1974
Legal implications of the package insertR Temple
JAMA|August 27, 1999
Are surrogate markers adequate to assess cardiovascular disease drugs?R Temple
American Heart Journal|April 30, 1999
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of government agencies regarding cost-effectiveness claims: FDA perspectiveR Temple
Pageof 40

Showing results (1-10 of 394) with videos related to

Sort By:
Pageof 40
JAMA|March 10, 1999
Meta-analysis and epidemiologic studies in drug development and postmarketing surveillanceR Temple
Clinical Pharmacology and Therapeutics|December 1, 1987
The clinical investigation of drugs for use by the elderly: Food and Drug guidelinesR Temple
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 1, 1985
FDA letter to radioactive drug research chairpersonsR Temple
American Heart Journal|March 31, 2000
Current definitions of phases of investigation and the role of the FDA in the conduct of clinical trialsR Temple
The American Journal of Cardiology|May 30, 1998
The challenge of regulating development and approval of drugs with pleiotropic action in cardiovascular diseaseR Temple
Clinical Pharmacology and Therapeutics|July 17, 2007
Quantitative decision analysis: a work in progressR Temple
Clinical Pharmacology and Therapeutics|October 15, 2010
Enrichment of clinical study populationsR Temple
The Medical Clinics of North America|September 1, 1974
Legal implications of the package insertR Temple
JAMA|August 27, 1999
Are surrogate markers adequate to assess cardiovascular disease drugs?R Temple
American Heart Journal|April 30, 1999
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of government agencies regarding cost-effectiveness claims: FDA perspectiveR Temple
Pageof 40